WEBULL
News
DTIL
3.810
+0.26%
0.010
Weekly Report: what happened at DTIL last week (0202-0206)?
Weekly Report · 14h ago
Weekly Report: what happened at DTIL last week (0126-0130)?
Weekly Report · 02/02 09:53
Weekly Report: what happened at DTIL last week (0119-0123)?
Weekly Report · 01/26 09:53
JonesTrading Keeps Their Buy Rating on Precision BioSciences (DTIL)
TipRanks · 01/23 12:56
Precision BioSciences 13G Filing Shows Empery Asset Management Reports 9.99% Stake In Co As Of December 31, 2025
Benzinga · 01/22 18:11
EMPERY ASSET MANAGEMENT LP REPORTS 9.99% PASSIVE STAKE IN PRECISION BIOSCIENCES AS OF DEC 31, 2025 - SEC FILING
Reuters · 01/22 18:06
Weekly Report: what happened at DTIL last week (0112-0116)?
Weekly Report · 01/19 09:57
Precision BioSciences Highlights 2026 Gene Editing Priorities
TipRanks · 01/13 21:28
Precision BioSciences Provides 2026 Business Update Emphasizing Progress In PBGENE-HBV And PBGENE-DMD Programs, Anticipated Clinical Data In 2026, And Strong $137M Cash Runway
Benzinga · 01/12 12:32
Precision Biosciences Advances Gene Therapy Pipeline With Ongoing Phase 1/2a ELIMINATE‑B Trial For PBGENE‑HBV And Anticipated Q1 2026 IND Clearance For PBGENE‑DMD; Data Updates Expected Throughout 2026
Benzinga · 01/12 12:19
Precision BioSciences Announces 2026 Strategic Plan Focused on Advancing Clinical-Stage PBGENE-HBV and PBGENE-DMD Programs, Initiating DMD Clinical Trials, and Maintaining Cash Runway Through 2028
Reuters · 01/12 12:02
Weekly Report: what happened at DTIL last week (0105-0109)?
Weekly Report · 01/12 09:56
Precision BioSciences Partner iECURE Secures FDA Alignment Toward BLA, RMAT Designation, And UK ILAP Innovation Passport For ECUR-506 In Neonatal OTC Deficiency
Benzinga · 01/07 13:08
Weekly Report: what happened at DTIL last week (1229-0102)?
Weekly Report · 01/05 09:53
Precision Biosciences Files Prospectus To Offer Up To $250M Securities
Benzinga · 12/30/2025 13:17
PRECISION BIOSCIENCES INC: FILES FOR MIXED SHELF OF UP TO $250 MLN - SEC FILING
Reuters · 12/30/2025 13:06
Weekly Report: what happened at DTIL last week (1222-1226)?
Weekly Report · 12/29/2025 09:52
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026
Seeking Alpha · 12/29/2025 08:40
Precision BioSciences Grants Inducement RSUs to New Employee
Reuters · 12/23/2025 12:00
PRECISION BIOSCIENCES ANNOUNCES GRANT OF INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/23/2025 12:00
More
Webull provides a variety of real-time DTIL stock news. You can receive the latest news about Precision Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About DTIL
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.